Use orotic acid in the treatment of pathological conditions associated with hyperuricemia
Journal Title: Нирки - Year 2014, Vol 4, Issue 10
Abstract
Hyperuricemia - a condition characterized by elevated relative to normal ranges, levels of uric acid in the blood. Among the diseases caused by hyperuricemia, most noteworthy are gout, urate nephropathy, and urolithiasis. The topic of this article is devoted to the comparative characteristics of drugs used to correct hyperuricemia. The main part of the article is an analysis of pharmacodynamics, efficacy, safety and expediency of using orotic acid agents.
Authors and Affiliations
Dmytro D. Ivanov, Y. Dombrovsky
Keywords
Related Articles
- EP ID EP225266
- DOI -
- Views 90
- Downloads 0
Precision diagnosis of lupus nephritis: opportunities and role of biomarkers
The most common complication in patients with systemic lupus erythematosus is lupus nephritis (LN), a condition that can lead to end-stage kidney disease. In recent years, many serum and urine biomarkers, genetic studies...
Additional diagnostic capabilities of water-salt loadings in patients with chronic kidney disease stage І–ІІІ
Background. The number of patients with chronic kidney disease (CKD) increases every year, including those requiring renal replacement therapy. According the Kidney Disease Improving Global Outcomes guidelines, we use th...
Pathophysiological Aspects of Acute Renal Injury
.
Comparative efficacy of different approaches to metaphylaxis of recurrent urinary tract infections
An open-label comparative prospective study of the clinical and laboratory efficacy and safety of Espa-Focin (fosfomycin trometamol) and Cysto-Aurin (goldenrod preparation) manufactured by Еsparma GmbH was performed in 1...
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney dis...